PTX 8.00% 4.6¢ prescient therapeutics limited

Ann: PTX-200 High Overall Response in Ph2a Breast Cancer trial, page-307

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 280 Posts.
    lightbulb Created with Sketch. 22
    My goodness! .... "In the lab, T-cells equipped with the new TCR were shown to kill lung, skin, blood, colon, breast, bone, prostate, ovarian, kidney and cervical cancer cells, while ignoring healthy cells." (In vivo mice with human cancers)

    Fantastic news for medicine ... but not so fantastic for we shareholders?

 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.